Jack A. Khattar - Feb 2, 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Feb 2, 2023
Transactions value $
-$342,286
Form type
4
Date filed
2/6/2023, 04:01 PM
Previous filing
Feb 3, 2023
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $215K +22.5K +2.83% $9.56 818K Feb 2, 2023 Direct F1
transaction SUPN Common Stock Sale -$569K -13.5K -1.65% $42.06 804K Feb 2, 2023 Direct F1, F2
transaction SUPN Common Stock Options Exercise $3.15K +330 +0.04% $9.56 804K Feb 3, 2023 Direct F1
transaction SUPN Common Stock Sale $8.4K +200 +0.02% $42.02 804K Feb 3, 2023 Direct F1, F3
holding SUPN Common Stock 1.05M Feb 2, 2023 By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -22.5K -47.02% $0.00 25.4K Feb 2, 2023 Common Stock 22.5K $9.56 Direct F1, F4
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -330 -1.3% $0.00 25K Feb 3, 2023 Common Stock 330 $9.56 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.09, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.03, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The options vested in four equal annual installments beginning on January 23, 2015.